How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

699 results for

Fludrocortisone

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. (PubMed)

Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. Septic shock is characterized by dysregulation of the host response to infection, with circulatory, cellular, and metabolic abnormalities. We hypothesized that therapy with hydrocortisone plus fludrocortisone or with drotrecogin alfa (activated), which can modulate the host response, would improve the clinical outcomes of patients with septic shock.In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design (...) , we evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (activated), the combination of the three drugs, or their respective placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included mortality at intensive care unit (ICU) discharge and hospital discharge and at day 28 and day 180 and the number of days alive and free of vasopressors, mechanical ventilation, or organ failure. After drotrecogin alfa (activated) was withdrawn from

2018 NEJM

2. Comments on: 'Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial'. (PubMed)

Comments on: 'Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial'. 29271586 2018 09 07 2018 12 02 1468-1331 25 1 2018 01 European journal of neurology Eur. J. Neurol. Comments on: 'Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial'. e4 10.1111/ene.13475 Simões R M RM 0000-0002-9566-6969 Neurology Department (...) Molecular, Lisbon, Portugal. Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal. eng Letter Comment England Eur J Neurol 9506311 1351-5101 0 Cholinesterase Inhibitors KVI301NA53 Pyridostigmine Bromide U0476M545B Fludrocortisone IM Eur J Neurol. 2017 Apr;24(4):545-551 28224720 Eur J Neurol. 2018 Feb;25(2):e27-e28 29356263 Blood Pressure Cholinesterase Inhibitors Fludrocortisone Humans Hypotension, Orthostatic Parkinson Disease Pyridostigmine

2018 European Journal of Neurology

3. Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. (PubMed)

Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. This study aimed at describing the pharmacokinetics and the concentration-effect relationships of fludrocortisone and hydrocortisone on urinary sodium/potassium excretion in healthy volunteers. This was a placebo-controlled, randomized, double blind, crossover study, of oral fludrocortisone and intravenous hydrocortisone, given alone or in combination, in 12 healthy (...) male volunteers. Nonlinear mixed-effects modeling was used to describe the pharmacokinetics and pharmacokinetic-pharmacodynamic relationships on urinary sodium/potassium ratio for each drug. A one-compartment model was used to describe fludrocortisone and hydrocortisone pharmacokinetics. Mean plasma half-life was 1.40 h (95%CI [0.80;2.10]) for fludrocortisone and 2.10 h (95%CI [1.78;2.40]) for hydrocortisone. Clearance was 40.8 L/h (95%CI [33.6;48]) for fludrocortisone and 30 L/h (95%CI [25.3;34.7

2018 The AAPS journal

4. Hydrocortisone plus fludrocortisone: Taichi of risk hedge for improving adults with septic shock (PubMed)

Hydrocortisone plus fludrocortisone: Taichi of risk hedge for improving adults with septic shock 30174942 2018 11 14 2072-1439 10 7 2018 Jul Journal of thoracic disease J Thorac Dis Hydrocortisone plus fludrocortisone: Taichi of risk hedge for improving adults with septic shock. E596-E597 10.21037/jtd.2018.07.18 Chen Wensen W Office of Infection Management, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Jiangsu 210029, China. Wang Yingqin Y Department

Full Text available with Trip Pro

2018 Journal of thoracic disease

5. Use of fludrocortisone for intradialytic hypotension (PubMed)

Use of fludrocortisone for intradialytic hypotension Intradialytic hypotension during dialysis adversely affects a patient's prognosis and increases mortality. We report a case in which intradialytic hypotension that persisted after the administration of midodrine was relieved after the use of fludrocortisone. Administration of 0.2 mg of fludrocortisone occurred 30 minutes before dialysis. We compared 45 sessions of dialysis without fludrocortisone administration and 45 sessions of dialysis (...) with fludrocortisone administration in one patient. The number of times in which systolic blood pressure became lower than 80 mmHg and the number of early terminations of dialysis due to a decrease in systolic blood pressure were higher in the sessions without fludrocortisone administration than in the sessions with fludrocortisone administration (P < 0.05). Fludrocortisone may be helpful for the treatment of intradialytic hypotension that does not respond to midodrine administration.

Full Text available with Trip Pro

2018 Kidney research and clinical practice

6. Salt Wasting, Hydro-sodium Balance and Fludrocortisone Requirement in Congenital Adrenal Hyperplasia

Salt Wasting, Hydro-sodium Balance and Fludrocortisone Requirement in Congenital Adrenal Hyperplasia Salt Wasting, Hydro-sodium Balance and Fludrocortisone Requirement in Congenital Adrenal Hyperplasia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Salt Wasting, Hydro-sodium Balance and Fludrocortisone Requirement in Congenital Adrenal Hyperplasia (NaCAH) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03550261

2018 Clinical Trials

7. Oral Fludrocortisone Test for Salt-Sensitive Screening in Hypertensive Patients: A Randomized Crossover Trial. (PubMed)

Oral Fludrocortisone Test for Salt-Sensitive Screening in Hypertensive Patients: A Randomized Crossover Trial. Salt sensitivity is associated with an increased cardiovascular risk, but the gold standard method (diet cycles) requires 24-h urine samples and has poor patient compliance.Test the hypothesis that oral fludrocortisone (0.4 mg per day for 7 days) is a good alternative in identifying salt-sensitive patients.We conducted a randomized crossover study with 30 hypertensive individuals (...) comprising the following steps: (1) washout; (2) phase A (low- and high-sodium diet cycles); (3) washout 2; (4) phase B (fludrocortisone test). Phase A and B steps were performed in a random way. Consistent with the literature, we found that 53.3% were salt-sensitive according to the reference test. Using the ROC curve, the fludrocortisone test defined salt sensitivity by a median blood pressure increase of ≥3 mmHg. A good accuracy of fludrocortisone in detecting salt sensitivity was observed (AUC: 0.732

Full Text available with Trip Pro

2018 International journal of hypertension

8. Safety and Efficacy of Fludrocortisone in the Treatment of Cerebral Salt Wasting in Patients With Tuberculous Meningitis: A Randomized Clinical Trial. (PubMed)

Safety and Efficacy of Fludrocortisone in the Treatment of Cerebral Salt Wasting in Patients With Tuberculous Meningitis: A Randomized Clinical Trial. Tuberculous meningitis is associated with high frequency of cerebral salt wasting. There is a paucity of objective information regarding the best method of treatment of this condition.To evaluate the efficacy and safety of fludrocortisone in the treatment of cerebral salt wasting in patients with tuberculous meningitis.This is a single-center (...) , open-label, randomized clinical trial conducted from October 2015 to April 2017 in India. Patients were randomized in a 1:1 ratio to arms receiving saline only or saline plus fludrocortisone, in addition to a standard treatment of 4 antitubercular drugs, prednisolone, and aspirin. The 2 arms were matched for demographic, clinical, and magnetic resonance imaging findings. The patients were followed up for at least 6 months.Patients were randomized to a 0.9% solution of intravenous saline with 5

2018 JAMA neurology

9. Fludrocortisone for the Prevention of Vasovagal Syncope: A Randomized, Placebo-Controlled Trial (PubMed)

Fludrocortisone for the Prevention of Vasovagal Syncope: A Randomized, Placebo-Controlled Trial There is limited evidence whether being on fludrocortisone prevents vasovagal syncope.The authors sought to determine whether treatment with fludrocortisone reduces the proportion of patients with recurrent vasovagal syncope by at least 40%, representing a pre-specified minimal clinically important relative risk reduction.The multicenter POST 2 (Prevention of Syncope Trial 2) was a randomized (...) , placebo-controlled, double-blind trial that assessed the effects of fludrocortisone in vasovagal syncope over a 1-year treatment period. All patients had >2 syncopal spells and a Calgary Syncope Symptom Score >-3. Patients received either fludrocortisone or matching placebo at highest tolerated doses from 0.05 mg to 0.2 mg daily. The main outcome measure was the first recurrence of syncope.The authors randomized 210 patients (71% female, median age 30 years) with a median 15 syncopal spells over

Full Text available with Trip Pro

2016 EvidenceUpdates

10. Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock.

Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock. Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Low Dose (...) of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock. (COCCA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03773822 Recruitment Status : Not yet recruiting First Posted : December 12, 2018 Last Update Posted : December

2018 Clinical Trials

11. Furosemide/Fludrocortisone Test and Clinical Parameters to Diagnose Incomplete Distal Renal Tubular Acidosis in Kidney Stone Formers. (PubMed)

Furosemide/Fludrocortisone Test and Clinical Parameters to Diagnose Incomplete Distal Renal Tubular Acidosis in Kidney Stone Formers. Incomplete distal renal tubular acidosis is a well known cause of calcareous nephrolithiasis but the prevalence is unknown, mostly due to lack of accepted diagnostic tests and criteria. The ammonium chloride test is considered as gold standard for the diagnosis of incomplete distal renal tubular acidosis, but the furosemide/fludrocortisone test was recently (...) proposed as an alternative. Because of the lack of rigorous comparative studies, the validity of the furosemide/fludrocortisone test in stone formers remains unknown. In addition, the performance of conventional, nonprovocative parameters in predicting incomplete distal renal tubular acidosis has not been studied.We conducted a prospective study in an unselected cohort of 170 stone formers that underwent sequential ammonium chloride and furosemide/fludrocortisone testing.Using the ammonium chloride

Full Text available with Trip Pro

2017 Clinical Journal of the American Society of Nephrology

12. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial. (PubMed)

Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial. Evidence for effective treatment options for orthostatic hypotension (OH) in Parkinson's disease (PD) is scarce. Elevation of cholinergic tone with pyridostigmine bromide has been reported as a way to improve blood pressure (bp) regulation in neurogenic hypotension without causing supine hypertension.This was a double-centre, double-blind, randomized (...) , active-control, crossover, phase II non-inferiority trial of pyridostigmine bromide for OH in PD (clinicaltrials.gov NCT01993680). Patients with confirmed OH were randomized to 14 days 3 × 60 mg/day pyridostigmine bromide or 1 × 0.2 mg/day fludrocortisone before crossover. Outcome was measured by peripheral and central bp monitoring during the Schellong manoeuvre and questionnaires.Thirteen participants were enrolled between April 2013 and April 2015 with nine participants completing each trial arm

Full Text available with Trip Pro

2017 European Journal of Neurology

13. Fludrocortisone therapy for persistent hyperkalaemia. (PubMed)

Fludrocortisone therapy for persistent hyperkalaemia. Type 4 renal tubular acidosis causes hyperkalaemia, for which diabetes and medications commonly used in this patient group are aetiological factors. Here we describe the novel use of fludrocortisone in this difficult condition.A 55-year-old woman with complex co-morbidities, including Type 2 diabetes (HbA1c 37 mmol/mol 5.5%), was admitted with renal failure. Bloods on admission: eGFR 25 ml/min, creatinine 184 ?mol/L, urea 35.9 mmol/L, sodium (...) days, she was commenced on fludrocortisone 50 mcg/day. Her renal function and serum potassium stabilized and she was discharged with potassium 4.3 mmol/L, eGFR 42 ml/min, and bicarbonate 23 mmol/L. She has remained stable on this treatment, without requiring further hospital admission for over 6 months, with eGFR 40 ml/min, and potassium 5.5 mmol/L, and albumin 26 g/L.This woman was presumed to have Type 4 renal tubular acidosis and recurrent hyperkalaemia due to renal insufficiency, in the context

2017 Diabetic Medicine

14. Fludrocortisone Is Associated With a Higher Risk of All‐Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic Hypotension (PubMed)

Fludrocortisone Is Associated With a Higher Risk of All‐Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic Hypotension Orthostatic hypotension causes ≈80 000 hospitalizations per year in the United States. Treatments for orthostatic hypotension include fludrocortisone, a mineralocorticoid analog that promotes sodium reabsorption; and midodrine, an α-1 adrenergic agonist that is a direct vasoconstrictor. Although both medications are used to treat orthostatic (...) hypotension, few studies have compared their relative safety.We compared incidence rates of hospitalizations for all causes, and for congestive heart failure between users of fludrocortisone and users of midodrine in a retrospective cohort study of Tennessee Medicaid adult enrollees (1995-2009). Adjusted incidence rate ratios were calculated using negative binomial regression models. Subgroup analyses based on history of congestive heart failure were conducted. We studied 1324 patients initiating

Full Text available with Trip Pro

2017 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

15. Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease (PubMed)

Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease 28674867 2018 11 30 1619-1560 27 Suppl 1 2017 07 Clinical autonomic research : official journal of the Clinical Autonomic Research Society Clin. Auton. Res. Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease. 29-31 10.1007/s10286-017-0434-6 Kremens Daniel D Department of Neurology, Thomas Jefferson (...) University, Philadelphia, PA, USA. Lew Mark M Department of Neurology, University of Southern California, Los Angeles, CA, USA. marklew@usc.edu. Claassen Daniel D Department of Neurology, Vanderbilt University, Nashville, TN, USA. Goodman Brent P BP Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ, USA. eng Letter Research Support, Non-U.S. Gov't 2017 07 03 Germany Clin Auton Res 9106549 0959-9851 Droxidopa Fludrocortisone Midodrine Neurogenic orthostatic hypotension Parkinson’s disease 2017

Full Text available with Trip Pro

2017 Clinical Autonomic Research

16. Primary Care Corner with Geoffrey Modest MD: Fludrocortisone for Vasovagal Syncope

Primary Care Corner with Geoffrey Modest MD: Fludrocortisone for Vasovagal Syncope Primary Care Corner with Geoffrey Modest MD: Fludrocortisone for Vasovagal Syncope | BMJ EBM Spotlight by By Dr. Geoffrey Modest Vasovagal syncope is pretty common, but there are no documented effective treatments. Fludrocortisone has potential by improving venous return: its efficacy was evaluated in the Prevention of Syncope Trial 2 — POST 2 trial (see Sheldon R. JACC 2016; 68: 1). Details: 210 patients (71 (...) % female, median age 30, BMI 24, HR 70 bpm, BP 112/70) with a mean of 15 syncopal episodes over 9 years Randomized to fludrocortisone at the highest tolerated doses (from 0.05-0.2 mg/d, titrated over 2 weeks, with most achieving the 0.2 mg dose) vs placebo and followed for 1 year Inclusion criteria: >13 yo, >2 lifetime syncopal episodes; exclusions: diabetes, hepatic disease BP>135/85, “significant comorbidities”, or if when standing 5 minutes they had postural tachycardia of >30 bpm, or orthostatic

2016 Evidence-Based Medicine blog

17. Pharmacokinetics of oral fludrocortisone in septic shock (PubMed)

Pharmacokinetics of oral fludrocortisone in septic shock The combination of hydrocortisone and fludrocortisone improved outcomes in septic shock. However, the specific role of fludrocortisone remains controversial and its pharmacokinetics (PK) has never been investigated in septic shock. This study aimed at characterizing the PK of fludrocortisone in septic shock.This was a single-centre ancillary PK study of a large multinational trial of crystalloids versus colloids for acute hypovolemia (...) in intensive care unit (ICU) patients. In 21 adults with septic shock, fludrocortisone plasma concentrations were measured by liquid chromatography-mass spectrometry tandem analysis, before and repeatedly until 18 h after an oral dose of 50 μg. PK parameters were estimated using a nonlinear mixed-effects modelling.Undetectable plasma concentrations were observed in 7 out of 21 patients. In the remaining 14 patients, plasma fludrocortisone concentrations were best described by a one-compartmental model

Full Text available with Trip Pro

2016 British journal of clinical pharmacology

18. Cerebral Salt Wasting Syndrome following Head Injury in a Child Managed Successfully with Fludrocortisone (PubMed)

Cerebral Salt Wasting Syndrome following Head Injury in a Child Managed Successfully with Fludrocortisone Cerebral salt wasting (CSW) syndrome is an important cause of hyponatremia in head injuries apart from syndrome of inappropriate antidiuretic hormone (SIADH). Proper diagnosis and differentiation between these two entities are necessary for management as the treatment is quite opposite in both conditions. Fludrocortisone can help in managing CSW where alone saline infusion does not work. We (...) report a 17-month-old female child with head injury managed successfully with saline infusion and fludrocortisone.

Full Text available with Trip Pro

2016 Case reports in pediatrics

19. Takotsubo-like syndrome triggered by fludrocortisone overdose for Addison’s disease: a case report (PubMed)

Takotsubo-like syndrome triggered by fludrocortisone overdose for Addison’s disease: a case report Reversible left ventricular dysfunction, also termed Takotsubo cardiomyopathy, is rarely reported in Addison's disease after initiation of hormone replacement therapy. The pathogenesis of this cardiomyopathy is unknown.A 41-year-old white woman with a history of autoimmune Hashimoto thyroiditis diagnosed 3 years earlier and acute adrenal insufficiency diagnosed 3 weeks earlier presented with new (...) onset of heart failure New York Heart Association class IV, which had started shortly after initiation of hormone replacement therapy with hydrocortisone 20 mg/day and fludrocortisone 0.3 mg/day. Nine days before admission she had collapsed because of dizziness and had a cerebral concussion and open fracture of her nasal bone, however, no further investigations were carried out at that time. A physical examination revealed leg edema, tachycardia, tachypnea, bilateral basal crepitations, and blood

Full Text available with Trip Pro

2016 Journal of medical case reports

20. Impact of the Administration of Fludrocortisone in Very Premature Infants

Impact of the Administration of Fludrocortisone in Very Premature Infants Impact of the Administration of Fludrocortisone in Very Premature Infants - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Impact (...) of the Administration of Fludrocortisone in Very Premature Infants (MINIPREM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03001089 Recruitment Status : Recruiting First Posted : December 22, 2016 Last Update Posted : March 2, 2018

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>